The company reiterated its long-term financial targets reflecting 12% to 14% growth of non-GAAP diluted EPS. The company also announced plans to realign its business to increase its focus on the core and accelerate its growth areas. Effective January 1, the company began operating under an updated enterprise operating and segment reporting structure, which includes two reportable segments Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution. Separate from these two segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics will be reported as Other. The company plans to report its second quarter fiscal 2024 results on February 1, according to its former reporting segments and will then report its third quarter fiscal 2024 results and forward on the basis of its updated structure.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CAH:
- Early notable gainers among liquid option names on January 3rd
- Barclays starts healthcare technology, distribution with Neutral view
- Cardinal Health initiated with an Overweight at Barclays
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Foot Locker upgraded, Deckers downgraded: Wall Street’s top analyst calls
